Physician profile
Rachel Lynn Sims
NPI 1245860410
$8,070.56
in general payments reported to CMS, 2019-2025
50 companies · $2,408 in 2025
The $2,408 reported for 2025 was more than what 98% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $429 · 2022: $956 · 2023: $2,240 · 2024: $2,038 · 2025: $2,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,685.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,039.22 | 2021-2025 | |
| Ucb, INC. | $759.57 | 2022-2025 | Zilbrysq, Briviact, Fintepla |
| Neurocrine Biosciences, INC. | $472.96 | 2021-2025 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $435.84 | 2022-2024 | Ultomiris, Soliris |
| Acadia Pharmaceuticals INC | $417.65 | 2021-2025 | Nuplazid |
| Amgen INC. | $388.91 | 2021-2025 | Uplizna |
| Sk Life Science, INC. | $382.57 | 2021-2025 | Xcopri |
| Argenx US, INC. | $327.99 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $238.99 | 2024-2025 | |
| Lundbeck LLC | $236.87 | 2023-2025 | Vyepti |
| Pfizer INC. | $233.95 | 2023-2025 | |
| Emd Serono, INC. | $232.77 | 2023-2025 | Mavenclad |
| Eisai INC. | $185.37 | 2023-2025 | |
| Lilly USA, LLC | $183.35 | 2022-2025 | Amyvid, Kisunla, Reyvow |
| Celgene Corporation | $179.82 | 2021-2025 | Zeposia |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $175.65 | 2022-2025 | |
| Merz North America, INC. | $163.22 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $142.35 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $140.29 | 2025 | Hyqvia |
| Acorda Therapeutics, INC | $128.98 | 2023-2024 | Ampyra, Inbrija |
| Otsuka America Pharmaceutical, INC. | $110.93 | 2023-2025 | Nuedexta, Rexulti |
| Biogen, INC. | $109.46 | 2023-2025 | Vumerity, Plegridy |
| Genzyme Corporation | $109.31 | 2023-2025 | |
| Avion Pharmaceuticals | $105.08 | 2021-2022 | |
| Horizon Therapeutics Plc | $104.70 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $99.33 | 2023-2025 | Austedo, Austedo Xr, Austedo Xr |
| Alnylam Pharmaceuticals INC. | $94.45 | 2023 | Onpattro |
| Octapharma USA, INC. | $91.97 | 2022-2023 | Panzyga |
| Genentech USA, INC. | $91.73 | 2025 | Ocrevus Zunovo, Ocrevus |
| Amneal Pharmaceuticals LLC | $72.66 | 2023 | Rytary |
| Scilex Pharmaceuticals INC. | $68.49 | 2023 | Ztlido |
| Biohaven Pharmaceutical Holding Company Ltd. | $64.82 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $64.66 | 2024 | |
| Kyowa Kirin, INC. | $43.02 | 2023-2024 | Nourianz |
| C2n Diagnostics, LLC | $38.55 | 2025 | Precivityad2 |
| Astrazeneca Pharmaceuticals Lp | $37.21 | 2023-2025 | Andexxa, Wainua |
| Insightec,INC | $27.68 | 2023 | Exablate |
| Vanda Pharmaceuticals INC. | $26.58 | 2024 | Ponvory |
| Springworks Therapeutics, INC. | $24.95 | 2025 | Gomekli |
| Axsome Therapeutics, INC. | $24.43 | 2024 | Sunosi |
| Jazz Pharmaceuticals INC. | $23.89 | 2024 | |
| Grifols USA, LLC | $22.65 | 2025 | Gamunex-C |
| Ipsen Biopharmaceuticals, INC | $21.55 | 2023 | Dysport |
| Corium, LLC | $20.83 | 2023 | Adlarity |
| Medtronic, INC. | $20.43 | 2024 | Intellis Adaptivestim |
| Neurelis, INC. | $19.06 | 2025 | Valtoco |
| Aprecia Pharmaceuticals, LLC | $17.98 | 2022 | |
| Sandoz INC. | $16.47 | 2023 | |
| Almatica Pharma LLC | $15.85 | 2022 | |
| Servier Pharmaceuticals LLC | $15.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.